Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Fiona Stacey is active.

Publication


Featured researches published by Fiona Stacey.


The American Journal of Clinical Nutrition | 1997

Are deficits of arachidonic and docosahexaenoic acids responsible for the neural and vascular complications of preterm babies

M.A. Crawford; Kate Costeloe; Kebreab Ghebremeskel; A. Phylactos; Louise Skirvin; Fiona Stacey

We review evidence suggesting that pre- or postnatal deficits of arachidonic acid (AA) and docosahexaenoic acid (DHA) together with underdeveloped antioxidant protection contribute to neurovisual developmental disorders and other complications of premature birth. These two synergistic deficits occur at a time when 70% of energy is focused on brain development and when the brain and blood vessels are growing at high speed. The types of essential fatty acids fed to preterm babies bear no relation to what the infant would have received had it remained a fetus. This failure to meet essential fatty acid requirements exacerbates the AA and DHA deficits seen at birth; furthermore, the immature superoxide defenses remain depressed until the expected date of delivery. Deficits of these systems, which are required for cell membranes, the endothelium, and neural tissue, could provide the biochemical prerequisite for the membrane disorders to which these babies are at high risk: intraventricular hemorrhage, periventricular leucomalacia, retinopathy of prematurity, and bronchopulmonary dysplasia. Although poor vascular development during fetal and neonatal life may be repaired, the structural and antioxidant deficits identified in preterm babies may impair blood vessel development with long-term consequences. The conclusion drawn from this review is that present parenteral and enteral lipid nutrition for preterm babies is flawed and could be pathogenic. Full-term milk composition is the basis for the design of preterm infant foods, but full-term milk is different from the placental product that is rich in AA and DHA. Preterm lipid nutrition should be revised to be more in line with placental lipid transfer to the fetus.


Journal of Clinical Microbiology | 2008

Colonization and persistence of antibiotic-resistant Enterobacteriaceae strains in infants nursed in two neonatal intensive care units in East London, United Kingdom.

Michael Millar; Alex Philpott; Mark Wilks; Angela Whiley; Simon Warwick; Enid Hennessy; Pietro G. Coen; Stephen T. Kempley; Fiona Stacey; Kate Costeloe

ABSTRACT Stool samples were collected from infants nursed in two neonatal intensive care units (NICUs) in East London, United Kingdom. The aim of the study was to determine the incidence of and risk factors for the carriage of multiresistant Enterobacteriaceae strains (MRE; resistant to three or more classes of antibiotic) and the extent of the persistence of resistant strains following discharge. Sixty-two (50%) of 124 infants had acquired MRE by 2 weeks of postnatal age, and 69 (56%) infants had acquired MRE by discharge. The proportions of infants at 2 weeks carrying strains that were resistant to antibiotics were the following: tetracycline, 79%; amoxicillin, 78%; cephalosporins, 31%; trimethoprim, 20%; piperacillin-tazobactam, 11%; chloramphenicol, 9%; and aminoglycoside, 4%. A gestational age of less than 26 weeks was a risk factor for colonization with MRE at discharge, but not at 2 weeks. Analysis within a NICU showed that exposure of an infant to a specific antibiotic in the NICU was not a risk factor for the carriage of a strain resistant to that antibiotic. Estimates of persistence from discharge to 6 months were the following: for tetracycline, 57% (95% confidence intervals [CI], 0.35 to 0.87); chloramphenicol, 49% (95% CI, 0.20 to 0.83); trimethoprim, 45% (95% CI, 0.22 to 0.74); piperacillin-tazobactam, 42% (95% CI, 0.20 to 0.71); and augmentin, 34% (95% CI, 0.11 to 0.66). Strains resistant to cephalosporins or aminoglycosides showed lower levels of persistence. Nine of 34 infants (26.5%) with Escherichia coli and 4 (7.1%) of 56 infants with Klebsiella spp. at discharge carried strains indistinguishable by randomly amplified polymorphic DNA and antibiotic susceptibility patterns at 6 months. MRE were found at high frequency in the infants during their stay in the NICU and persisted in a proportion of infants.


British Journal of Obstetrics and Gynaecology | 2012

An investigation into the reporting and management of late terminations of pregnancy (between 22 +0 and 26 +6 weeks of gestation) within NHS Hospitals in England in 2006: the EPICure preterm cohort study.

Elizabeth S Draper; Zarko Alfirevic; Fiona Stacey; Enid Hennessy; Kate Costeloe

Please cite this paper as: Draper E, Alfirevic Z, Stacey F, Hennessy E, Costeloe K, for the EPICure Study Group. An investigation into the reporting and management of late terminations of pregnancy (between 22+0 and 26+6 weeks of gestation) within NHS Hospitals in England in 2006: the EPICure preterm cohort study. BJOG 2012;119:710–715.


Health Technology Assessment | 2016

A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial

Kate Costeloe; Ursula Bowler; Peter Brocklehurst; Pollyanna Hardy; Paul Heal; Edmund Juszczak; Andrew J. King; Nicola Panton; Fiona Stacey; Angela Whiley; Mark Wilks; Michael Millar


Tijdschrift Voor Kindergeneeskunde | 2013

Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies)

Kate Costeloe; Enid Hennessy; S Haider; Fiona Stacey; Neil Marlow; Es. Draper


Archive | 2016

Guidance sheet 3: preparation and administration of the trial intervention

Kate Costeloe; Ursula Bowler; Peter Brocklehurst; Pollyanna Hardy; Paul Heal; Edmund Juszczak; Andrew J. King; Nicola Panton; Fiona Stacey; Angela Whiley; Mark Wilks; Michael Millar


Archive | 2016

Probiotics in Preterm infantS trial sites

Kate Costeloe; Ursula Bowler; Peter Brocklehurst; Pollyanna Hardy; Paul Heal; Edmund Juszczak; Andrew J. King; Nicola Panton; Fiona Stacey; Angela Whiley; Mark Wilks; Michael Millar


Archive | 2016

Form 1: trial entry

Kate Costeloe; Ursula Bowler; Peter Brocklehurst; Pollyanna Hardy; Paul Heal; Edmund Juszczak; Andrew J. King; Nicola Panton; Fiona Stacey; Angela Whiley; Mark Wilks; Michael Millar


Archive | 2016

Parent information leaflet version 5.1

Kate Costeloe; Ursula Bowler; Peter Brocklehurst; Pollyanna Hardy; Paul Heal; Edmund Juszczak; Andrew J. King; Nicola Panton; Fiona Stacey; Angela Whiley; Mark Wilks; Michael Millar


Archive | 2016

Form 4: abdominal pathology

Kate Costeloe; Ursula Bowler; Peter Brocklehurst; Pollyanna Hardy; Paul Heal; Edmund Juszczak; Andrew J. King; Nicola Panton; Fiona Stacey; Angela Whiley; Mark Wilks; Michael Millar

Collaboration


Dive into the Fiona Stacey's collaboration.

Top Co-Authors

Avatar

Kate Costeloe

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Angela Whiley

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nicola Panton

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Paul Heal

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge